The South Korean government has officially introduced a bold strategic roadmap to transform its medical sector through the 2nd Basic Plan for Advanced Regenerative Medicine and Advanced Biopharmaceuticals. This five-year initiative, spanning the period from 2026 to 2030, aims to establish a
The landscape of oncology has reached a pivotal juncture where terminal diagnoses for aggressive blood cancers are increasingly being redefined by the success of durable, long-term immunotherapy outcomes. Recent five-year clinical data for lisocabtagene maraleucel, commonly referred to as liso-cel,
Ivan Kairatov is a seasoned Biopharma expert with a distinguished career in research and development, specializing in the technological innovations that drive drug discovery. His deep understanding of protein dynamics and structural biology makes him a leading voice in deciphering the complex
The rapid evolution of therapeutic interventions in the oncology sector has necessitated a fundamental shift in how clinical success is quantified, moving beyond immediate tumor shrinkage toward a comprehensive evaluation of patient outcomes over several years. Historically, the primary metrics for
The persistent challenge of delivering life-saving genetic material across the nearly impenetrable blood-brain barrier has long remained the single greatest hurdle in the field of modern neurology and neurosurgery. A sophisticated gene therapy platform, recently detailed in the journal Nature
Ivan Kairatov stands at the forefront of biotechnological innovation, bringing years of deep-seated experience in research and development within the biopharma sector. As an expert who has witnessed the evolution of gene therapy from experimental theory to life-saving reality, he offers a unique
